Polyrizon Ltd. (PLRZ) Form 6-K — Oct 27, 2026
Polyrizon (Nasdaq: PLRZ) announced on October 27, 2026 the successful completion of patient enrollment and randomization in its U.S. multicenter clinical study of NASARIX, its investigational nasal hydrogel designed to protect against airborne allergens. All 120 planned participants were randomized across five U.S. clinical sites, with 144 individuals screened to reach the target.
Key figures
- Study Design
- Randomized, controlled study of NASARIX vs saline control in adults with allergic rhinitis
- Clinical Sites
- 5
- Enrolled Patients
- 120
- Screened Individuals
- 144
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.